Sheth RD. Bone health in pediatric epilepsy[J]. Epilepsy Behav, 2004, 5(Suppl 2):S30-S35.
[2]
Oner N, Kaya M, Karasalihoğlu S, et al. Bone mineral metabolism changes in epileptic children receiving valproic acid[J]. J Paediatr Child Health, 2004, 40(8):470-473.
[3]
Lee RH, Lyles KW, Colón-Emeric C. A review of the effect of anticonvulsant medications on bone mineral density and fracture risk[J]. Am J Geriatr Pharmacother, 2010, 8(1):34-46.
[4]
Serin HM, Koç ZP, Temelli B, et al. The bone mineral content alterations in pediatric patients medicated with levetiracetam, valproic acid, and carbamazepine[J]. Epilepsy Behav, 2015, 51:221-224.
[5]
Anwar MJ, Radhakrishna KV, Vohora D. Phenytoin and sodium valproate but not levetiracetam induce bone alterations in female mice[J]. Can J Physiol Pharmacol, 2014, 92(6):507-511.
[6]
Yaghini O, Tonekaboni SH, Amir Shahkarami SM, et al. Bone mineral density in ambulatory children with epilepsy[J]. Indian J Pediatr, 2015, 82(3):225-229.
[7]
Miziak B, Błaszczyk B, Chrościńska-Krawczyk M, et al. The problem of osteoporosis in epileptic patients taking antiepileptic drugs[J]. Expert Opin Drug Saf, 2014, 13(7):935-946.
[8]
Bauer S, Hofbauer LC, Rauner M, et al. Early detection of bone metabolism changes under different antiepileptic drugs (ED-BoM-AED)-a prospective multicenter study[J]. Epilepsy Res, 2013, 106(3):417-422.
[9]
Shiek Ahmad B, O'Brien TJ, Gorelik A, et al. Bone mineral changes in epilepsy patients during initial years of antiepileptic drug therapy[J]. J Clin Densitom, 2016, 19(4):450-456.
[10]
Dimić M, Dimić A, Milosević Z, et al. Bone mineral density in children with long-term antiepileptic therapy[J]. Srp Arh Celok Lek, 2013, 141(5-6):329-332.
[11]
Baek JH, Seo YH, Kim GH, et al. Vitamin D levels in children and adolescents with antiepileptic drug treatment[J]. Yonsei Med J, 2014, 55(2):417-421.
[12]
Lin CM, Fan HC, Chao TY, et al. Potential effects of valproate and oxcarbazepine on growth velocity and bone metabolism in epileptic children-a medical center experience[J]. BMC Pediatr, 2016, 16:61.
[13]
Paino F, La Noce M, Tirino V, et al. Histone deacetylase inhibition with valproic acid downregulates osteocalcin gene expression in human dental pulp stem cells and osteoblasts:evidence for HDAC2 involvement[J]. Stem Cells, 2014, 32(1):279-289.
[14]
Humphrey EL, Morris GE, Fuller HR. Valproate reduces collagen and osteonectin in cultured bone cells[J]. Epilepsy Res, 2013, 106(3):446-450.
[15]
Wilson EL, Garton M, Fuller HR, et al. Anti-epileptic drugs and bone loss:Phenytoin reduces pro-collagen I and alters the electrophoretic mobility of osteonectin in cultured bone cells[J]. Epilepsy Res, 2016, 122:97-101.
[16]
Fan HC, Lee HS, Chang KP, et al. The impact of anti-epileptic drugs on growth and bone metabolism[J]. Int J Mol Sci, 2016, 17(8). pii:E1242.
[17]
Villegas-Martínez I, de-Miguel-Elízaga I, Carrasco-Torres R, et al. The COL1A1 SP1 polymorphism is associated with lower bone mineral density in patients treated with valproic acid[J]. Pharmacogenet Genomics, 2016, 26(3):126-132.
[18]
Hamed SA. Markers of bone turnover in patients with epilepsy and their relationship to management of bone diseases induced by antiepileptic drugs[J]. Expert Rev Clin Pharmacol, 2016, 9(2):267-286.
[19]
Albaghdadi O, Alhalabi MS, Alourfi Z, et al. Bone health and vitamin D status in young epilepsy patients on valproate monotherapy[J]. Clin Neurol Neurosurg, 2016, 146:52-56.
[20]
Vera V, Moran JM, Barros P, et al. Greater calcium intake is associated with better bone health measured by quantitative ultrasound of the phalanges in pediatric patients treated with anticonvulsant drugs[J]. Nutrients, 2015, 7(12):9908-9917.
[21]
Albaghdadi O, Alhalabi MS, Alourfi Z, et al. Bone health and vitamin D status in young epilepsy patients on valproate monotherapy[J]. Clin Neurol Neurosurg, 2016, 146:52-56.
[22]
Vestergaard P. Effects of antiepileptic drugs on bone health and growth potential in children with epilepsy[J]. Paediatr Drugs, 2015, 17(2):141-150.
[23]
Lazzari AA, Dussault PM, Thakore-James M, et al. Prevention of bone loss and vertebral fractures in patients with chronic epilepsy-antiepileptic drug and osteoporosis prevention trial[J]. Epilepsia, 2013, 54(11):1997-2004.
[24]
Anwar MJ, Radhakrishna KV, Sharma A, et al. Raloxifene preserves phenytoin and sodium valproate induced bone loss by modulating serum estradiol and TGF-β3 content in bone of female mice[J]. Eur J Pharm Sci, 2014, 62:219-226.
